

wherein the antigen binding region of non-human origin comprises at least one framework region containing a substitution of at least one amino acid to a corresponding amino acid in the III2R heavy chain framework region or the H2F light chain framework region.

2. (Twice Amended). The humanized immunoglobulin of Claim 1, wherein the portion of an immunoglobulin of human origin is a human constant region.

8. (Amended). The humanized immunoglobulin of Claim 1, wherein the antigen binding region comprises a complementarity determining region of rodent origin, and the portion of an immunoglobulin of human origin is at least a portion of a human framework region.

15. (Twice Amended). A humanized immunoglobulin having binding specificity for B7-2, wherein said immunoglobulin has a binding affinity of at least about 10^7 M^{-1} , and wherein said humanized immunoglobulin is derived from the cell line deposited with the ATCC®, Accession No. CRL-12524.

21. (Twice Amended). A humanized immunoglobulin light chain having binding specificity for B7-2, wherein said immunoglobulin has a binding affinity of at least about 10^7 M^{-1} , and wherein said immunoglobulin comprises CDR1, CDR2 and CDR3 of the light chain of the murine 3D1 antibody, and further wherein the immunoglobulin comprises at least one framework region containing a substitution of at least one amino

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

acid to a corresponding amino acid in the framework region of the light chain of the human H2F antibody.

25. (Twice Amended). A humanized immunoglobulin heavy chain specific for B7-2 wherein said immunoglobulin has a binding affinity of at least about 10^7 M^{-1} , and wherein said immunoglobulin comprises CDR1, CDR2 and CDR3 of the heavy chain of the murine 3D1 antibody, and further wherein the immunoglobulin comprises at least one framework region containing a substitution of at least one amino acid to a corresponding amino acid in the framework region of the heavy chain of the human III2R antibody.

30. (Twice Amended). An expression vector comprising a fused gene encoding a humanized immunoglobulin light chain, said gene comprising a nucleotide sequence encoding a CDR derived from a nonhuman antibody having binding specificity for B7-2, wherein said immunoglobulin has a binding affinity of at least about 10^7 M^{-1} , further wherein the immunoglobulin comprises at least one framework region containing a substitution of at least one amino acid to a corresponding amino acid in the framework region of the light chain of the human H2F antibody.

33. (Twice Amended). An expression vector comprising a fused gene encoding a humanized immunoglobulin heavy chain, said gene comprising a nucleotide sequence encoding a CDR derived from a heavy chain of a nonhuman antibody having binding

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

specificity for B7-2, wherein said immunoglobulin has a binding affinity of at least about 10^7 M^{-1} , further wherein the immunoglobulin comprises at least one framework region containing a substitution of at least one amino acid to a corresponding amino acid in the framework region of the heavy chain of the human III2R antibody.

40. (Twice Amended). A fused gene encoding a humanized immunoglobulin light chain having binding specificity for B7-2, wherein said immunoglobulin has a binding affinity of at least about 10^7 M^{-1} , comprising:

- a) a first nucleic acid molecule encoding an antigen binding region derived from the murine 3D1 monoclonal antibody, further wherein the immunoglobulin comprises at least one framework region containing a substitution of at least one amino acid to a corresponding amino acid in the framework region of the light chain of the human H2F antibody; and
- b) a second nucleic acid sequence encoding at least a portion of a constant region of an immunoglobulin of human origin.

75. (Amended). A fused gene encoding a humanized immunoglobulin heavy chain having binding specificity for B7-2, wherein said immunoglobulin has a binding affinity of at least about 10^7 M^{-1} , comprising:

- a) a first nucleic acid molecule encoding an antigen binding region derived from the murine 3D1 monoclonal antibody, further wherein the immunoglobulin comprises at least one framework region containing a substitution of at least one amino

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com